GlaxoSmithKline PLC ADR (GSK) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US37733W2044
GlaxoSmithKline PLC ADR financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 31.38 bn GBP | 32.67 bn GBP |
| Gross profit | 22.33 bn GBP | 23.65 bn GBP |
| Operating income | 4.02 bn GBP | 7.93 bn GBP |
| EBIT | 4.02 bn GBP | 8.34 bn GBP |
| Net income | 2.58 bn GBP | 5.72 bn GBP |
| Diluted EPS – continuing operations | 1.24 GBP | 5.60 GBP |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
More stocks
- RWE Aktiengesellschaft (RWE.PR)
- Galderma Group AG (GALD.SW)
- Lenovo Group Ltd (992.HK)
- Elevra Lithium Ltd (SYADB.AX)
- AutoZone (AZO)
- Wabtec (WAB)
- Coca-Cola Europacific Partners PLC (CCEP)
- ArcelorMittal SA (MT.AS)
- Autodesk (ADSK)
- Veeva Systems (VEEV)
- Commerzbank (CBK.DE)
- Fujikura Ltd (5803.T)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.